Toggle navigation
Campus Access
About MPG.eBooks
Skip to content
Search Tips
Home
>
Search: "the arts"
Language
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
All Fields
Title
Person
Topic
ISBN/ISSN
Year
Collection
Advanced
Retain my current filters
author_facet:"Canadian Agency for Drugs and Technologies in Health"
language:"English"
Search alternatives
:
"the arts" »
"the art"
Showing
1
-
16
of
16
Search:
'"the arts"'
,
query time: 0.06s
Book List
0
Sort:
Relevance
Year Descending
Year Ascending
Author
Title
Read Now
1
Sensory rooms for patients with dementia in long-term care : clinical and cost-effectiveness, and guidelines
by
Banerjee, Srabani
,
Ford, Caitlyn
Published 2018
CADTH
Subjects:
“
...Sensory
Art
Therapies / methods...
”
Read Now
2
Pharmacoeconomic review report: Emtricitabine/tenofovir alafenamide (Descovy)
Published 2016
Canadian Agency for Drugs and Technologies in Health
“
... in combination with other antiretroviral therapies (
ARTs
) for the treatment of HIV type 1 infection in adults...
”
Read Now
3
Pharmacoeconomic review report: Emtricitabine/tenofovir alafenamide (Descovy)
Published 2016
Canadian Agency for Drugs and Technologies in Health
“
... in combination with other antiretroviral therapies (
ARTs
) for the treatment of HIV type 1 infection in adults...
”
Read Now
4
Common drug review new combination product: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate fixed-dose combination (Delstrigo) Merck Canada Inc. : indication: a complete regime...
Published 2019
CADTH
“
... in the mid-1990s, antiretroviral therapy (
ART
) has improved steadily with the availability of newer potent...
”
Read Now
5
Common drug review new combination product: Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate fixed-dose combination (Delstrigo) Merck Canada Inc. : indication: a complete regime...
Published 2019
CADTH
“
... in the mid-1990s, antiretroviral therapy (
ART
) has improved steadily with the availability of newer potent...
”
Read Now
6
Pharmacoeconomic review report: Cabotegravir tablets, cabotegravir extended-release injectable suspension, and rilpivirine extended-release injectable suspension (Vocabria, Cabenuv...
Published 2020
Canadian Agency for Drugs and Technologies in Health
“
... (
ARTs
)...
”
Read Now
7
Clinical review report: Dolutegravir (Tivicay)
Published 2014
Canadian Agency for Drugs and Technologies in Health
“
... in antiretroviral drugs(
ART
)-naive and
ART
-experienced patients...
”
Read Now
8
Clinical review report: Dolutegravir (Tivicay)
Published 2014
Canadian Agency for Drugs and Technologies in Health
“
... in antiretroviral drugs(
ART
)-naive and
ART
-experienced patients...
”
Read Now
9
Common drug review new combination product submission: Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide (Symtuza) : (Janssen Canada Inc.)
Published 2018
Canadian Agency for Drugs and Technologies in Health
“
...HIV is a chronic condition that can be managed through treatment with antiretroviral therapy (
ART
...
”
Read Now
10
Common drug review new combination product submission: Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide (Symtuza) : (Janssen Canada Inc.)
Published 2018
Canadian Agency for Drugs and Technologies in Health
“
...HIV is a chronic condition that can be managed through treatment with antiretroviral therapy (
ART
...
”
Read Now
11
CADTH Canadian Drug Expert Committee recommendation: Dolutegravir/Lamivudine (Dovato -- ViiV healthcare ULC) : indication: as a complete regimen for the treatment of human immunode...
Published 2019
CADTH
“
... be naive to any antiretroviral therapy (
ART
) and have an HIV-1 viral load ≤ 500,000 copies/mL. The patient...
”
Read Now
12
CADTH Canadian Drug Expert Committee recommendation: Dolutegravir/Lamivudine (Dovato -- ViiV healthcare ULC) : indication: as a complete regimen for the treatment of human immunode...
Published 2019
CADTH
“
... be naive to any antiretroviral therapy (
ART
) and have an HIV-1 viral load ≤ 500,000 copies/mL. The patient...
”
Read Now
13
Clinical review report: Tesamorelin (Egrifta) : indication : treatment of excess visceral adipose tissue (VAT), as assessed by waist circumference ≥ 95 cm for males and ≥ 94 cm for...
Published 2016
CADTH
“
... or to specific antiretroviral therapy (
ART
) regimens. Evidence suggests that the use of protease inhibitors...
”
Read Now
14
Clinical review report: Tesamorelin (Egrifta) : indication : treatment of excess visceral adipose tissue (VAT), as assessed by waist circumference ≥ 95 cm for males and ≥ 94 cm for...
Published 2016
CADTH
“
... or to specific antiretroviral therapy (
ART
) regimens. Evidence suggests that the use of protease inhibitors...
”
Read Now
15
Pharmacoeconomic review report: Dolutegravir/Lamivudine (Dovato) (ViiV healthcare ULC) : indication: as a complete regimen for the treatment of human immunodeficiency virus type1 (...
Published 2019
CADTH
Read Now
16
Pharmacoeconomic review report: Dolutegravir/Lamivudine (Dovato) (ViiV healthcare ULC) : indication: as a complete regimen for the treatment of human immunodeficiency virus type1 (...
Published 2019
CADTH
Back
Narrow Search
Remove Filters
Clear Filter
Author: Canadian Agency for Drugs and Technologies in Health
Clear Filter
Language: English
Year of Publication
From:
To:
Classification
610 - Medicine & health
11
330 - Economics
5
363 - Other social problems & services
1
700 - The arts; fine & decorative arts
1
Language
English
Collection
National Center for Biotechnology Information
16
Author
Canadian Agency for Drugs and Technologies in Health
CADTH Canadian Drug Expert Committee
2
Banerjee, Srabani
1
Ford, Caitlyn
1
Recently Uploaded
Last Month
1
Search Tools
Get RSS Feed
Share Search
https://ebooks.mpdl.mpg.de/ebooks/Search/Results?filter%5B%5D=author_facet%3A%22Canadian+Agency+for+Drugs+and+Technologies+in+Health%22&filter%5B%5D=language%3A%22English%22&lookfor=%22the+arts%22&type=AllFields
Send by Email
×
Loading...